Antibody development and disease severity of COVID-19 in non-immunised patients with rheumatic immune-mediated inflammatory diseases: data from a prospective cohort study.
Laura BoekelFemke HooijbergErik H VogelzangYaëlle R BestenMaureen LeeuwSadaf AtiqiRonald F Van VollenhovenCarla A WijbrandtsMartijn GerritsenCharlotte Lm KrieckaertBas DijkshoornSiham BakhlakhJuliette J CrooijmansAlexandre VoskuylIrene E van der Horst-BruinsmaWillem F LemsTaco W KuijpersS Marieke van HamLuuk WieskeFilip EftimovLaura Y KummerPj Koos van DamEileen W StalmanMaurice SteenhuisSofie KeijzerOlvi CristianawatiJim KeijserFloris C LoeffSander W TasMichael T NurmohamedMaarten BoersTheo RispensGertjan WolbinkPublished in: RMD open (2022)
We observed that patients with rheumatic IMIDs, especially those treated with B-cell targeting therapy, were more likely to be hospitalised when infected with SARS-CoV-2. Treatment with conventional synthetic disease-modifying antirheumatic drugs (DMARDs) and biological DMARDs other than B-cell targeting agents is unlikely to have negative effects on the development of long-lasting humoral immunity against SARS-CoV-2.